FATE
Fate Therapeutics Inc.
Company Overview
| Mkt Cap | $137.24M | Price | $2.09 |
| Volume | 4.12M | Change | +6.63% |
| P/E Ratio | -1.0 | Open | $2.00 |
| Revenue | $6.6M | Prev Close | $1.96 |
| Net Income | $-136.3M | 52W Range | $0.91 - $2.88 |
| Div Yield | N/A | Target | $5.41 |
| Overall | 64 | Value | 60 |
| Quality | 42 | Technical | 90 |
No chart data available
About Fate Therapeutics Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Latest News
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)
5 Healthcare Stocks Set to Join the Russell 3000
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FATE | $2.09 | +6.6% | 4.12M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |